9.8 C
New York
Tuesday, October 20, 2026
- Advertisement -spot_img

TAG

azenosertib

Azenosertib Ovarian Cancer Data Shows 15.8-Month Survival

Zentalis reported 15.8-month median overall survival for azenosertib in ovarian cancer patients, with full data due at ESMO Congress on Oct 23.

Latest news

- Advertisement -spot_img